These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8239624)

  • 21. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.
    Wakebe H; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2185-91. PubMed ID: 1332589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
    Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of HSR-903, a new quinolone.
    Takahashi Y; Masuda N; Otsuki M; Miki M; Nishino T
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1326-30. PubMed ID: 9174193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
    Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.
    Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Heifetz CL
    Diagn Microbiol Infect Dis; 1991; 14(5):403-15. PubMed ID: 1665775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of T-3761, a new fluoroquinolone.
    Muratani T; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
    Barry AL; Fuchs PC
    Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro antibacterial activities of broad spectrum quinolones against clinical bacterial isolates].
    Ishii Y; Ohno A; Yamaguchi K
    Jpn J Antibiot; 1994 Jan; 47(1):22-8. PubMed ID: 8114270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM; Laskowski R; Bjarnason J; Stewart C
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
    Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
    Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
    Pechère JC; Gootz TD
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activity of temafloxacin for gram-positive pathogens.
    Bille J; Glauser MP
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():9-14. PubMed ID: 1664835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H; Stepanik D; Vilches V; Scarano S; Sarachian B; Mikaelian G; Finlay J; Sucari A
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antibacterial activities of piperacillin in several fresh clinical isolates].
    Matsuzaki K; Koyama H; Omika K; Hasegawa M; Sato Y; Kobayashi I; Kaku M
    Jpn J Antibiot; 2000 Aug; 53(8):573-81. PubMed ID: 11070819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.